The Million-Dollar Mistake: How Bad mRNA Design Is Burning Your Runway

Your company has raised or committed millions. You've assembled a brilliant team. You've identified a compelling therapeutic target. And you're about to flush a significant portion of that investment down the drain because of something most companies overlook: mRNA sequence design.

‍

The Expensive Shortcut

Here's a scenario we've witnessed repeatedly: A company raises a Series A. They're moving their lead candidate toward IND-enabling studies. They order mRNA using a sequence they've modified from the wild-type or run through an optimization tool. The material arrives. They move forward with studies.

Then reality hits.

Expression is lower than models predicted. Protein levels drop off faster than expected. Animal models show inconsistent results. Manufacturing struggles with batch variability. Suddenly, the runway that seemed comfortable starts looking alarmingly short.

The knee-jerk reaction? Blame formulation. Tinker with delivery. Change the animal model. Another round of protein engineering. But a critically important element — the mRNA sequence — almost always goes unoptimized. And for good reason: the complexity and challenge of finding a better sequence has historically been a nearly insurmountable challenge. Terrain’s computational design stack is changing that.

‍

Let's Talk Numbers

The financial impact of poor sequence design is staggering:

• Failed late stage studies: $250-500k each time you need to repeat work
• Manufacturing overruns: Up to $2M in additional costs when low-integrity mRNA requires multiple GMP runs
• Timeline extensions: Each month of delay also burns $500k-1M in operational costs for a typical Series A company
• Increased dose requirements: Poor expression means higher doses, multiplying material costs by 2-5x and a subsequent risk of increasing immunogenicity 

These "hidden fees" can easily consume 20-30% of your total funding or budget—money that should be advancing your pipeline, not compensating for fixable design problems.

Imagine a promising gene therapy startup, Quill Therapeutics. After raising a $40 million Series A, they're advancing their lead candidate toward IND-enabling studies with a timeline to reach the clinic in 18 months.

Quill decides to save money by optimizing their sequence in-house and uses a vendor’s generic optimization tool to improve their sequence a bit more. The initial $75k for sequence and material seems reasonable compared to their overall budget.

Six months later, things have gone well in their in vitro studies but as they move to animal studies, the problems begin:

• Month 7: Initial animal studies show inconsistent expression. The team blames delivery and repeats the study with modified formulation. Cost: $200-300k and 8 weeks lost.
• Month 9: New studies show marginally better results but still below therapeutic threshold. A senior scientist suggests the sequence itself might be the issue, but lacking the tools to optimize their sequence, the team instead decides to fiddle with their formulation again. Cost: 8 more weeks lost.
• Month 11: Their latest study shows improved results but still below therapeutic threshold. Behind schedule and over budget, leadership begins to push them to move to IND with subpar results.

The total cost of the “economical” approach?

• Direct costs: Hundreds of thousands to millions in cash burn
• Opportunity cost: Competitors have advanced while you troubleshoot
• Fundraising impact: With less data than planned, your next raise becomes an “if” instead of a “when” 

And the potential final verdict? The program is delayed and puts the fate of the company in question.

‍

VC Perspective: The Overlooked Red Flag

Venture investors are increasingly recognizing poor mRNA design as a silent killer of otherwise promising companies. This scrutiny will only increase as the field matures and the correlation between well-designed sequences and program success becomes more evident.

‍

The Simple Question That Could Save You Millions

Before you commit to your next set of studies, ask yourself one question: Do I actually know if my mRNA sequence is optimized for success, or am I just hoping it's good enough?

If you can't specifically explain how your sequence was designed to address:

• Tissue-specific optimization 
• Translation efficiency in your specific context
• Secondary structure engineering for stability and durable expression
• UTR optimization for tunable, targeted regulation of expression
• Avoidance of immune-stimulating motifs
• Compatibility with GMP manufacturing processes

...then you're likely building your program on a fundamentally flawed foundation.

The most expensive sequence isn't the one that costs more upfront for proper design—it's the cheap one that forces you to redo all your work. Terrain helps you do the work once, the right way.

‍

‍P.S. Design + Build: The Force Multiplier

Having the perfect sequence design is only half the equation. You also need to build it and do so with high quality. At Terrain, we've integrated our design platform with world-class build capabilities. This means our partners don't just get superior designs—they get them manufactured and ready for testing. And with our rapid turnaround times, they get their mRNA in a fraction of the time it takes other providers.

Terrain’s integrated design+build approach means you can:

• Iterate through design cycles faster
• Validate sequences in weeks, not months
• Reduce handoff errors between design and production

The result? Better sequences, seamless design-build integration, and validated constructs so you can get your next round of data fast.